MA44763A - Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang - Google Patents
Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sangInfo
- Publication number
- MA44763A MA44763A MA044763A MA44763A MA44763A MA 44763 A MA44763 A MA 44763A MA 044763 A MA044763 A MA 044763A MA 44763 A MA44763 A MA 44763A MA 44763 A MA44763 A MA 44763A
- Authority
- MA
- Morocco
- Prior art keywords
- antigen
- antibodies
- intended
- pharmaceutical compositions
- dendritic cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328959P | 2016-04-28 | 2016-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44763A true MA44763A (fr) | 2019-03-06 |
Family
ID=58672794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044763A MA44763A (fr) | 2016-04-28 | 2017-04-27 | Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190284281A1 (enExample) |
| EP (1) | EP3448425A1 (enExample) |
| JP (3) | JP7045327B2 (enExample) |
| KR (5) | KR20240033168A (enExample) |
| CN (2) | CN109475623B (enExample) |
| AU (2) | AU2017258191B2 (enExample) |
| BR (1) | BR112018072125A2 (enExample) |
| CA (1) | CA3022116A1 (enExample) |
| CO (1) | CO2018012506A2 (enExample) |
| EA (1) | EA201892443A1 (enExample) |
| IL (2) | IL262514B2 (enExample) |
| MA (1) | MA44763A (enExample) |
| MX (3) | MX2018012945A (enExample) |
| NZ (2) | NZ747504A (enExample) |
| PH (1) | PH12018502278A1 (enExample) |
| WO (1) | WO2017189827A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3672981A4 (en) * | 2017-08-22 | 2021-09-15 | Biogen MA Inc. | PROCESSES FOR PURIFYING ANTIBODIES PRESENTING REDUCED AGGREGATES WITH HIGH MOLECULAR WEIGHT |
| EP3823594B1 (en) | 2018-07-19 | 2025-02-05 | Ichnos Sciences S.A. | Liquid antibody formulation |
| KR200494676Y1 (ko) | 2020-08-04 | 2021-12-01 | (주) 티나인 | 버튼식 헤어 염색기 |
| AR124247A1 (es) * | 2020-12-03 | 2023-03-01 | Biogen Ma Inc | Métodos de tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico |
| CN118055781A (zh) | 2021-08-09 | 2024-05-17 | 株式会社茵温特拉 | 注入到生物体内后以不被巨噬细胞吞噬和/或不被代谢分解的状态通过肾脏由尿液排出的纳米结构物 |
| TW202400652A (zh) * | 2022-05-25 | 2024-01-01 | 大陸商映恩生物製藥（蘇州）有限公司 | 抗ｂｄｃａ２抗體及其用途 |
| TW202432188A (zh) * | 2022-12-28 | 2024-08-16 | 大陸商映恩生物製藥（蘇州）有限公司 | 抗ｂｄｃａ２抗體－藥物偶聯物及其用途 |
| WO2025067469A1 (zh) * | 2023-09-28 | 2025-04-03 | 南京维立志博生物科技股份有限公司 | Bdca2单克隆抗体及其和taci组成的融合蛋白及其方法和用途 |
| CN118638234B (zh) * | 2024-07-04 | 2025-10-14 | 杭州博之锐生物制药有限公司 | 抗bdca2抗体及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0403964B8 (pt) | 2003-04-04 | 2021-05-25 | Genentech Inc | formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige |
| WO2014093396A1 (en) * | 2012-12-10 | 2014-06-19 | Biogen Idec Ma Inc. | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
-
2017
- 2017-04-27 MX MX2018012945A patent/MX2018012945A/es unknown
- 2017-04-27 KR KR1020247007023A patent/KR20240033168A/ko not_active Ceased
- 2017-04-27 AU AU2017258191A patent/AU2017258191B2/en active Active
- 2017-04-27 JP JP2018556446A patent/JP7045327B2/ja active Active
- 2017-04-27 CA CA3022116A patent/CA3022116A1/en active Pending
- 2017-04-27 KR KR1020187034043A patent/KR102366547B1/ko active Active
- 2017-04-27 EA EA201892443A patent/EA201892443A1/ru unknown
- 2017-04-27 KR KR1020247035142A patent/KR20240159012A/ko not_active Ceased
- 2017-04-27 BR BR112018072125-5A patent/BR112018072125A2/pt active Search and Examination
- 2017-04-27 MA MA044763A patent/MA44763A/fr unknown
- 2017-04-27 CN CN201780032450.0A patent/CN109475623B/zh active Active
- 2017-04-27 NZ NZ747504A patent/NZ747504A/en unknown
- 2017-04-27 EP EP17722325.2A patent/EP3448425A1/en active Pending
- 2017-04-27 CN CN202310503830.5A patent/CN116850282A/zh active Pending
- 2017-04-27 US US16/095,475 patent/US20190284281A1/en not_active Abandoned
- 2017-04-27 KR KR1020257018429A patent/KR20250088784A/ko active Pending
- 2017-04-27 WO PCT/US2017/029802 patent/WO2017189827A1/en not_active Ceased
- 2017-04-27 KR KR1020227005469A patent/KR20220028150A/ko not_active Ceased
- 2017-04-27 NZ NZ787392A patent/NZ787392A/en unknown
-
2018
- 2018-10-22 IL IL262514A patent/IL262514B2/en unknown
- 2018-10-23 MX MX2023008075A patent/MX2023008075A/es unknown
- 2018-10-23 MX MX2025000037A patent/MX2025000037A/es unknown
- 2018-10-26 PH PH12018502278A patent/PH12018502278A1/en unknown
- 2018-11-22 CO CONC2018/0012506A patent/CO2018012506A2/es unknown
-
2022
- 2022-03-18 JP JP2022043702A patent/JP2022084782A/ja active Pending
-
2024
- 2024-01-10 JP JP2024001801A patent/JP2024038308A/ja active Pending
- 2024-05-15 AU AU2024203240A patent/AU2024203240A1/en active Pending
-
2025
- 2025-02-21 US US19/060,474 patent/US20250289895A1/en active Pending
- 2025-06-17 IL IL321561A patent/IL321561A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44763A (fr) | Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang | |
| EP3357508A4 (en) | STABLE PHARMACEUTICAL ANTI-PD-1 ANTIBODY PREPARATION AND APPLICATION THEREOF IN MEDICINE | |
| EP3840730A4 (en) | COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND METHOD OF USE AND MANUFACTURING THEREOF | |
| EP3630145A4 (en) | PHARMACEUTICAL COMPOSITIONS OF CANNABIDIOL AND BETA-CARYOPHYLLENE AND METHOD FOR USING THEM | |
| EP3716945A4 (en) | LIQUID DOSAGE FORMS, METHOD OF MANUFACTURING AND USE | |
| EP3528823A4 (en) | DETERMINIST LATERAL SHIFTING IN THE PRODUCTION OF CELLS AND COMPOSITIONS FOR THERAPEUTIC USE | |
| MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
| EP3645063A4 (en) | SILK HYALURONIC ACID TISSUE FILLERS AND METHOD OF USING THEREOF | |
| EP3684423A4 (en) | VARIANT CAPSID WITH ADENO-ASSOCIATED VIRUS AND METHOD OF USE THEREOF | |
| MA45280A (fr) | Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation | |
| MA33989B1 (fr) | Formulation d'anticorps et régimes thérapeutiques | |
| EP2528603A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN AND OTHER DISPLAYS | |
| EP2558493A4 (en) | ANTIBODIES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-MEDIATED INFECTIONS AND DISEASES | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| EP3400013A4 (en) | CADHERIN-17 SPECIFIC ANTIBODIES AND CYTOTOXIC CELL TREATMENT CELLS | |
| MA54563A (fr) | Agents de comblement tissulaire à base de soie-acide hyaluronique et leurs procédés de préparation et d'utilisation | |
| EP2914505A4 (en) | DEVICE FOR ORAL RELEASE OF LIQUIDS AND HALF-RESISTANT FOODS | |
| EP3380525A4 (en) | PHARMACEUTICAL FORMULATIONS AND METHOD FOR USE THEREOF | |
| MA55090A (fr) | Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifs | |
| MA49947A (fr) | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes | |
| EP3873941A4 (en) | ANTI-HUMAN PD-1 ANTIBODY CRYSTALS AND METHODS OF USE THEREOF | |
| EP3418305A4 (en) | METHOD OF EXPRESSING AND PREPARING BIVALENT BISPEICIFIC ANTIBODY HYBRID PROTEIN | |
| MA41326A (fr) | Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation | |
| MA53466A (fr) | Formulation stable d'anticorps anti-osmr | |
| EP3362096A4 (en) | OPHTHALMIC TREATMENT COMPOSITION AND CARRIER FOR THE RELEASE OF PHARMACEUTICAL SUBSTANCES OR THERAPEUTICS |